trending Market Intelligence /marketintelligence/en/news-insights/trending/rxg65_gnj4-b1dpn7w-vfa2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

GlaxoSmithKline adds 2 execs to board

State Of Singapore Online Video Subscription

Power Forecast Briefing: Capacity Shortfalls to Test the Renewable Energy Transition

Episode 43 - More Change, M&A On Horizon For Equity Research Industry

Cable Nets Struggle With Little Revenue Growth Expanding Programming Budgets


GlaxoSmithKline adds 2 execs to board

GlaxoSmithKline PLC named CEO Designate Emma Walmsley and President of R&D Patrick Vallance to the board as executive directors, effective Jan. 1, 2017.

Stacey Cartwright will step down from the board, effective Dec. 31. She leaves after serving for almost 6 years as a nonexecutive director.

In addition, Andrew Witty and Moncef Slaoui will step down from the board March 31, 2017. Slaoui will serve as adviser to the company and the board from April 1, 2017, until his retirement June 30, 2017.